SC rejects bail plea of doctor accused of prescribing cough syrup linked to 26 child deaths

The Supreme Court refused bail because it viewed the allegations as exceptionally serious. Twenty-six children died after being linked to Coldrif syrup, and charges had only recently been framed. The bench also noted that the stockist was Soni’s relative, suggesting connections needing closer examination. His status as a qualified paediatrician increased the court’s concern.

Soni’s lawyer argued that he only prescribed the syrup and neither made nor produced it. The court focused instead on the alleged knowledge surrounding the prescriptions. It said the case could carry life imprisonment unless Soni could establish that he lacked the required knowledge. The court therefore dismissed the petition rather than deciding his guilt.

Soni may renew his bail plea after one year. That permission does not guarantee release. It allows the court to reconsider bail later, when more time may have passed and circumstances, evidence, or the trial’s progress may have changed. The Madhya Pradesh high court had earlier rejected his second bail application.

Bail is a court-approved release from custody while a criminal case proceeds. It does not mean the accused has been found innocent. A person released on bail must follow conditions set by the court and return when required. The purpose is to balance personal liberty with the need for a fair and effective investigation or trial.

A court may deny bail when allegations are extremely serious, punishment could be severe, or important evidence and relationships need closer examination. It may also consider risks such as influencing witnesses, obstructing the case, or avoiding court. In Soni’s case, the Supreme Court highlighted 26 deaths, recently framed charges, and the stockist’s family connection.

Bail decisions are separate from the final verdict. The Supreme Court did not determine whether Soni was guilty. It dismissed his petition at this stage but allowed him to apply again after a year. That reflects a possible change in circumstances, not a finding that the allegations have been proved.

The case involved 26 children’s deaths in Madhya Pradesh, according to the article. Laboratory reports cited by prosecutors found diethylene glycol, or DEG, in Coldrif syrup at levels reaching 46.28% weight by volume. The permitted limit was 0.1%.

Comparing those figures shows the reported concentration was 462.8 times the permitted limit. That comparison matters because the difference is not a small testing variation. It indicates an extremely high reported presence of a toxic industrial solvent in medicine given to children. The article links the affected children to acute kidney injuries and several deaths.

The first linked child death was reported in Chhindwara on September 4, 2025. The syrup allegedly continued to be prescribed as more cases emerged. Soni was arrested on October 5, 2025, and faces charges including culpable homicide not amounting to murder and provisions of the Drugs and Cosmetics Act.

Diethylene glycol, or DEG, is a toxic industrial solvent. The article identifies it as a chemical used in products such as brake fluid and antifreeze. It is not described as a safe ingredient for children’s medicine at the reported concentrations. Its presence in Coldrif was central to the prosecution’s case.

The key danger is damage to the kidneys. Exposure can cause acute kidney injury, meaning the kidneys suddenly lose their ability to work properly. Severe injury can progress to kidney failure and death. The article says children are particularly vulnerable, and links the contaminated syrup to children who developed acute kidney injuries before referral to a medical college hospital in Nagpur.

Laboratory reports cited by prosecutors found DEG levels as high as 46.28% by volume, compared with a permitted limit of 0.1%. The article reports 26 child deaths. It does not provide a detailed medical account of the chemical’s biological pathway, but it identifies kidney damage as the critical life-threatening effect.

A doctor does not need to manufacture a medicine to face consequences if prosecutors allege that the doctor knowingly prescribed a dangerous product. Possible consequences can include arrest, criminal charges, custody, trial, loss of liberty, and professional scrutiny. The exact outcome depends on evidence and the law, and guilt must still be proved in court.

In Soni’s case, prosecutors alleged that he continued prescribing Coldrif after warnings and while children developed kidney injuries. They also alleged that he received a 10% commission per bottle and that his wife sold the syrup through a nearby pharmacy. The Supreme Court said the case could attract life imprisonment unless the prosecution’s required knowledge was not established.

Soni’s defence says he was neither the manufacturer nor involved in production, and that the syrup was made under a valid licence. The court rejected bail at this stage, not the defence at trial. The case therefore shows that prescribing decisions, alleged knowledge, and financial links may all become important.

The article identifies two alleged warnings. A Central Drugs Standard Control Organization circular dated December 18, 2023, prohibited fixed-dose combination cough syrups for children below four years. Prosecutors also claimed that a senior paediatrician in Nagpur warned Soni about a similar DEG-contaminated cough syrup tragedy in Delhi in 1998.

These warnings mattered because the affected children were reportedly between two and four years old. The prosecution says Soni continued prescribing Coldrif despite the restriction and the earlier caution. The first linked death was reported on September 4, 2025, yet the syrup allegedly continued to be prescribed as more cases appeared.

The article also mentions a legal safeguard raised by Soni’s defence. His counsel relied on the Supreme Court’s 2005 judgment in Jacob Mathew v State of Punjab, which required appropriate expert opinion before criminal prosecution of medical practitioners. Whether the alleged warnings were received, understood, and legally sufficient remains part of the case.

Medicine safety is usually managed in stages. Manufacturers test products, meet quality standards, and seek a licence before sale. Regulators review licensing information, inspect production, monitor reports after marketing, and can restrict or recall products when serious risks appear. Doctors must prescribe responsibly, while pharmacies should dispense medicines lawfully and maintain proper records. Exact rules vary by country.

Responsibility depends on what each party knew and did. A manufacturer may face action for contamination or poor production. A doctor may face scrutiny for prescribing despite warnings or unsafe patient information. A pharmacy may be examined for selling improperly or without prescriptions. Regulators may investigate licensing, testing, warnings, and recall decisions. Evidence determines whether conduct was negligent, unlawful, or unrelated.

The article says Coldrif was manufactured by Sresan Pharmaceuticals Ltd under a valid licence, while prosecutors focused on Soni’s alleged prescribing and knowledge. It also describes alleged pharmacy sales and a regulatory restriction. It does not explain the full testing, monitoring, or recall process, so responsibility remains a matter for investigation and trial.